How to Safely Stop Reclast (Zoledronic Acid)

How Zoledronic Acid Works in Bone

Zoledronic acid is the most potent commercially available bisphosphonate, and its mechanism explains why stopping it differs from stopping nearly every other osteoporosis drug. The molecule binds to hydroxyapatite at sites of active remodeling, gets internalized by osteoclasts during resorption, and inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway 2. Without FPPS activity, osteoclasts lose their ruffled border, detach from bone, and undergo apoptosis.

Why Skeletal Half-Life Matters for Discontinuation

Unlike denosumab, which clears from serum within roughly six months, zoledronic acid embeds in the bone matrix itself. As old bone is slowly remodeled, small amounts of the drug re-release and suppress newly recruited osteoclasts. Pharmacokinetic modeling estimates a skeletal half-life exceeding 10 years 3. This reservoir effect is the pharmacologic basis for drug holidays: residual drug continues working long after the last infusion.

Osteoclast Suppression Versus Bone Quality

Three years of annual zoledronic acid reduces serum C-terminal telopeptide (CTX) by 50 to 60% from baseline. After the last dose, CTX rises slowly but typically remains below pretreatment levels for three to five years 4. Bone formation markers (P1NP) follow a similar trajectory. This prolonged suppression preserves microarchitecture without the overcorrection concerns sometimes raised with decade-long oral bisphosphonate use.

The HORIZON Trial: Foundation for Stopping Rules

The HORIZON Key Fracture Trial (HORIZON-PFT) randomized 7,765 postmenopausal women with osteoporosis to annual IV zoledronic acid 5 mg or placebo for three years. Zoledronic acid reduced morphometric vertebral fractures by 70% (3.3% vs. 10.9%, relative risk 0.30; 95% CI 0.24 to 0.38) and hip fractures by 41% 1.

The Extension Study That Defined the Holiday Window

HORIZON's extension phase (HORIZON-PFT Extension) re-randomized patients who had received three years of zoledronic acid to either three more years of active drug or placebo. The placebo group (effectively a drug holiday) maintained hip BMD and had only a modest increase in vertebral fracture risk 4. Morphometric vertebral fracture rates were 3.0% in the extension group vs. 6.2% in the holiday group over three years. For women without prevalent vertebral fractures and with femoral neck T-scores above −2.5, the absolute risk difference was clinically small.

The 2024 AACE osteoporosis guidelines cite this extension as the primary evidence that a three-to-six-year holiday is reasonable after three annual IV infusions, particularly for patients not classified as high or very high risk 5.

Who Should Not Take a Holiday

The HORIZON extension also identified a subgroup that benefited from continued therapy: women with prevalent vertebral fractures or femoral neck T-scores of −2.5 or below after three years of treatment. The Endocrine Society's 2020 guideline recommends against drug holidays in patients with a hip T-score at or below −2.5, a history of osteoporotic fracture during treatment, or those taking glucocorticoids at 5 mg/day or more of prednisone equivalent 6.

Step-by-Step Discontinuation Protocol

Stopping zoledronic acid is not a matter of simply skipping the next infusion and walking away. A structured protocol reduces the chance of undetected bone loss. The following approach synthesizes recommendations from the Endocrine Society, AACE, and the American Society for Bone and Mineral Research (ASBMR) 6 7.

Step 1: Assess Holiday Eligibility (Month 0)

Before the scheduled fourth infusion, review three data points:

• Femoral neck T-score: must be above −2.5 on most recent DXA.
• Fracture history on therapy: any incident clinical or morphometric vertebral fracture during the three treatment years disqualifies a holiday.
• Glucocorticoid use: patients on chronic oral glucocorticoids (prednisone 5 mg/day or equivalent) should continue therapy.

If all three criteria are met, defer the fourth infusion and enter monitoring.

Step 2: Obtain Baseline Bone Turnover Markers (Month 0 to 3)

Draw fasting serum CTX and P1NP within three months of the last infusion. These values anchor future comparisons. A CTX below 150 pg/mL and a P1NP below 35 mcg/L are typical suppressed values after three years of IV zoledronic acid.

Step 3: Schedule Monitoring Intervals

• Year 1 of holiday: repeat serum CTX and P1NP at 12 months.
• Year 2: DXA (hip and spine) plus bone turnover markers.
• Years 3 through 6: annual bone turnover markers, DXA every two years.

The 2020 Endocrine Society guideline notes that a rise in CTX above the premenopausal reference range (typically above 300 pg/mL) signals loss of residual drug effect and warrants reassessment 6.

Step 4: Define Restart Triggers

Resume antiresorptive therapy if any of the following occur during the holiday:

• New clinical fracture (vertebral or nonvertebral) at a typical osteoporotic site.
• Femoral neck or total hip T-score decline to −2.5 or below.
• Bone turnover markers rising above the premenopausal mean for two consecutive measurements.
• Significant height loss (more than 2 cm), prompting vertebral fracture assessment by DXA or lateral spine imaging.

Restarting can mean another course of zoledronic acid or, depending on clinical context, a switch to denosumab or an anabolic agent such as romosozumab or teriparatide.

How Long Can a Drug Holiday Last?

Data from HORIZON and observational cohorts suggest that the residual antifracture benefit of IV zoledronic acid persists for approximately three years after three annual infusions and may extend to six years in lower-risk patients 4. A 2020 meta-analysis of bisphosphonate holiday studies found that fracture risk began rising around year three of a holiday for oral bisphosphonates but was delayed to years four through six for IV zoledronic acid, consistent with its longer skeletal retention 8.

Comparing Holiday Windows Across Bisphosphonates

Oral alendronate's skeletal half-life is shorter, and the FLEX trial showed BMD declines beginning within one to two years of stopping after five years of treatment 9. Risedronate's residual effect fades even faster. Zoledronic acid's longer holiday window is one of its clinical advantages: fewer total infusions and a longer interval before retreatment.

Real-World Holiday Duration Data

A 2023 cohort study from the Danish National Patient Registry (N=4,218 zoledronic acid users) found that fracture incidence did not significantly increase until 4.5 years after the last infusion, and then only in patients whose baseline T-scores were between −2.5 and −2.0 10. Patients with post-treatment T-scores above −2.0 showed no significant increase through six years of follow-up.

Why Zoledronic Acid Does Not Cause Rebound Bone Loss

Clinicians familiar with denosumab discontinuation often worry about rebound vertebral fractures after stopping any potent antiresorptive. That concern does not apply to bisphosphonates. Denosumab is a circulating monoclonal antibody: once it clears, osteoclast activity surges above pretreatment levels, bone turnover spikes, and vertebral fracture risk rises sharply within 7 to 12 months 11.

The Hydroxyapatite Reservoir Effect

Zoledronic acid, by contrast, is physically sequestered in the mineral phase. It cannot be cleared by hepatic or renal metabolism. Bone turnover rises gradually, not abruptly, because drug re-release during normal remodeling continues to partially inhibit each new generation of osteoclasts. Multiple studies confirm no rebound increase in fracture incidence after zoledronic acid discontinuation 4 8.

Transitioning From Denosumab to Zoledronic Acid

For patients who need to stop denosumab (due to side effects, preference, or planned treatment duration), a single dose of zoledronic acid given six months after the last denosumab injection can prevent the rebound bone loss that would otherwise occur. The DATA-Switch trial demonstrated that this approach maintained BMD at 12 months in 89% of patients 12. This is a common clinical scenario and a frequent reason zoledronic acid appears in a discontinuation discussion even when it is not the drug being stopped.

Monitoring Bone Turnover Markers During the Holiday

Bone turnover markers are the earliest signal that the residual drug effect is fading. They change months to years before DXA detects meaningful BMD loss.

CTX: The Resorption Marker

Serum CTX reflects current osteoclast activity. Draw it fasting, in the morning, to minimize diurnal variation. After three annual zoledronic acid infusions, CTX values typically sit between 100 and 200 pg/mL. A rise above 300 pg/mL on two consecutive draws three months apart suggests clinically significant reactivation of resorption 6.

P1NP: The Formation Marker

Procollagen type 1 N-terminal propeptide (P1NP) tracks osteoblast-driven bone formation. Because formation is coupled to resorption, P1NP rises after CTX does. Monitoring both markers together gives a more complete picture of remodeling status than either alone.

Practical Interpretation

A pattern of stable CTX with slowly rising P1NP is normal during the first two years of a holiday and does not require intervention. The concerning pattern is CTX rising above the premenopausal mean while P1NP remains relatively suppressed, which could indicate uncoupled resorption. Any marker result should be interpreted alongside DXA trends, fracture history, and clinical risk factors rather than treated as a standalone trigger.

Special Populations and Considerations

Patients on Glucocorticoids

The American College of Rheumatology recommends against bisphosphonate holidays in patients receiving chronic glucocorticoids because steroid-induced bone loss continues regardless of residual bisphosphonate 13. If a patient starts glucocorticoid therapy during a zoledronic acid holiday, reassess DXA and consider restarting treatment.

Men With Osteoporosis

HORIZON-RFT (the recurrent fracture trial) included men and demonstrated fracture reduction with zoledronic acid after hip fracture 14. Holiday data in men is limited, but the Endocrine Society applies the same T-score and fracture-based criteria used for postmenopausal women 6. Monitor identically.

Renal Impairment

Zoledronic acid is contraindicated at creatinine clearance below 35 mL/min. Patients whose renal function declines during a holiday may not be eligible for retreatment with zoledronic acid. In such cases, denosumab (which is not renally cleared) is the standard alternative, although it requires its own careful discontinuation planning.

Patients Previously Treated With Oral Bisphosphonates

Some patients switch to IV zoledronic acid after years of oral alendronate or risedronate. Total bisphosphonate exposure matters: the ASBMR 2020 task force notes that patients with five or more years of prior oral therapy plus three years of IV therapy may have accumulated enough skeletal drug to support a longer holiday, though prospective data are lacking 7.

When to Restart and What to Use

Restarting therapy is not a failure. It is built into the protocol. The question is which agent to choose.

Resuming Zoledronic Acid

If the original three-year course produced good BMD gains and the patient tolerated infusions well, resuming annual IV zoledronic acid for one to three additional years is reasonable. There is no lifetime cap defined in guidelines, although most clinicians aim for cumulative treatment durations of six to ten years, interspersed with holidays 5.

Switching to an Anabolic Agent

For patients who fracture despite prior bisphosphonate therapy, the 2020 Endocrine Society guideline recommends considering romosozumab (210 mg SC monthly for 12 months) or teriparatide (20 mcg SC daily for up to 24 months) before resuming an antiresorptive 6. The ARCH trial (N=4,093) showed that romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone over 24 months 15.

Switching to Denosumab

Denosumab 60 mg SC every six months is an option when retreatment with a bisphosphonate is contraindicated (e.g., new renal impairment or esophageal stricture preventing oral options). Remember that denosumab itself will eventually require a discontinuation plan, ideally a consolidation dose of zoledronic acid.

The American Society for Bone and Mineral Research recommends documenting the holiday plan, restart criteria, and responsible clinician in the medical record at the time of the last bisphosphonate dose so that follow-through does not depend on patient recall alone 7.